The risk of cancer in patients with psoriasis: A population-based cohort study in Taiwan

Journal of the American Academy of Dermatology

Volumn 65, Issue 1, 2011, Pages 84-91

  Chen, Yi Ju ^a,c   Wu, Chun Ying ^a,b,c   Chen, Tzeng Ji ^c,d   Shen, Jui Lung ^a   Chu, Szu Ying ^c,d   Wang, Chang Bi ^a   Chang, Yun Ting ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETRETIN; HYDROXYUREA; METHOTREXATE; PSORALEN; RETINOL DERIVATIVE; VITAMIN D;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GALLBLADDER CANCER; GROUPS BY AGE; HUMAN; LARYNX CANCER; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OROPHARYNX CANCER; PHOTOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIASIS; SEX DIFFERENCE; SKIN CANCER; TAIWAN;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PSORIASIS; PUVA THERAPY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 79958785663     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.04.046     Document Type: Article

References (51)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
2. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984;10:965-8. (Pubitemid 14111149)
3. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol 2009;89:262-6.
4. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998;90:1278-84. (Pubitemid 28433472)
5. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997;336:1041-5. (Pubitemid 27163855)
6. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-83. (Pubitemid 32577862)
7. Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7. (Pubitemid 34032784)
8. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141:108-12. (Pubitemid 29333701)
9. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201. (Pubitemid 44413165)
10. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9. (Pubitemid 37433132)
11. Chang HJ, Lin HC, Lee HC, Lin CC, Pfeiffer S. Risk of mortality among depressed younger patients: a five-year follow-up study. J Affect Disord 2009;113:255-62.
12. Shao PL, Chie WC, Wang CY, Yang CY, Lu CY, Chang LY, et al. Epidemiology of Haemophilus influenzae type b meningitis in Taiwan, 1997 and 2000. J Microbiol Immunol Infect 2004;37:164-8.
13. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-8.e12 Epub 2009 Aug 5.
14. Wu CY, Wu CH, Wu MS, Wang CB, Cheng JS, Kuo KN, et al. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009;7:427-31.
15. Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol 2009;161:854.60. Epub 2009 Apr 30.
16. Gau CS, Chang IS, Lin Wu FL, Yu HT, Huang YW, Chi CL, et al. Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan. Pharmacoepidemiol Drug Saf 2007;16:86-95.
17. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
18. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 2009;129:2604-12. Epub 2009 May 14.
19. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700-3.
20. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008;26:S62-5.
21. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008;159:2-9.
22. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9. (Pubitemid 350277763)
23. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3.
24. Lindegard B. Mortality and causes of death among psoriatics. Dermatologica 1989;179:91-2.
25. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30. (Pubitemid 38461682)
26. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237-42. (Pubitemid 29111349)
27. Olsen JH, Moller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992;27:716-22.
28. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90. (Pubitemid 30415349)
29. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988;91:197-201.
30. Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990;22:1056-60. (Pubitemid 20186129)
31. Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 1997;108:897-900.
32. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006;142:1132-5. (Pubitemid 44414396)
33. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, Lindelof B, Berne B, Hannuksela M, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999;141:497-501. (Pubitemid 29448411)
34. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6. (Pubitemid 15016489)
35. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64:ii18-23.
36. Man I, Crombie IK, Dawe RS, Ibbotson SH, Ferguson J. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005;152:755-7. (Pubitemid 40571310)
37. Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004;84:370-4. (Pubitemid 39312270)
38. Paul C, Le TA, Cayuela JM, Devidas A, Robert C, Molinie V, et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 1997;133:867-71. (Pubitemid 27337547)
39. Ebeo CT, Girish MR, Byrd RP, Roy TM, Mehta JB. Methotrexate-induced pulmonary lymphoma. Chest 2003;123:2150-3. (Pubitemid 36706748)
40. Khopkar U, Bhor U. Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy. Indian J Dermatol Venereol Leprol 2008;74:379-82.
41. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-6. (Pubitemid 36513069)
42. Watabe H, Soma Y, Obara W, Murakami N, Kawase A, Mizukami T, et al. Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine. Acta Derm Venereol 2006;86:184-5. (Pubitemid 44020197)
43. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992;26:836-40.
44. Lelievre JD, Sacre K, Adle-Biassette H, Molinier-Frenkel V, Gaulard P, Papo T. Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol 2005;52:24-7.
45. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003;149:170-3. (Pubitemid 36966529)
46. Corazza M, Zampino MR, Montanari A, Altieri E, Virgili A. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003;206:330-3. (Pubitemid 36677019)
47. Fozza C, Dore F, Bonfigli S, Podda L, Longinotti M. Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia. Eur J Dermatol 2005;15:271-3. (Pubitemid 41020856)
48. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34:322-31.
49. Clarke LE, Junkins-Hopkins J, Seykora JT, Adler DJ, Elenitsas R. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. J Am Acad Dermatol 2007;56:686-90. (Pubitemid 46400185)
50. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, et al. Remissionof lymphoma after withdrawal ofmethotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 2007;82:1106-9. (Pubitemid 350209856)
51. Maruani A, Wierzbicka E, Machet MC, Abdallah-Lotf M, de MA, Machet L. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J Am Acad Dermatol 2007;57:S69-71.